Search - tctmd.com

Displaying 241 - 260 of 700

Sort: Relevancy | Date

Presentation TCT 2015

CoreValve Evolut R (Medtronic)

Presenter: Samir R. Kapadia, Nicolo Piazza, Torsten P. Vahl

October 13, 2015

Presentation TCT 2015

CoreValve Latin American Experience

Presenter: Jose A. Condado, Celin Malkun, Carlos D Calderas

October 13, 2015

News Conference News TCT 2015

Updates to CoreValve Extreme Risk Study Encouraging

October 13, 2015

News Industry News

Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations

October 13, 2015

Presentation TCT 2015

CoreValve US Extreme Risk: Evaluation of a Self-Expanding Transcatheter Aortic Valve in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery

Presenter: Spencer B. King III, Jagat Narula, James B. Hermiller Jr

October 12, 2015

News Conference News TCT 2015

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

October 12, 2015

Presentation TCT 2015

Updates From the US CoreValve Studies 2: Reports From Selected Substudies

Presenter: Samir R. Kapadia, Jeffrey J. Popma

October 11, 2015

Presentation TCT 2015

Updates From the US CoreValve Studies 1: Follow-up From the Extreme and High-Risk Subgroups

Presenter: Samir R. Kapadia, Jeffrey J. Popma, Michael J. Reardon

October 11, 2015

News Conference News TCT 2015

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Conference News TCT 2015

Asian TAVR Registry Shows Good Procedural and Clinical Results

October 11, 2015

News Daily News

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

L.A. McKeown

October 08, 2015

News Daily News

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

L.A. McKeown

October 08, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Daily News

在采用TAVR的早期，在试验中心以外接受治疗的患者的死亡率并非更高

October 01, 2015

News Daily News

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

October 01, 2015

News Daily News

En los Albores de la TAVR, No Hubo Más Mortalidad en Pacientes tratados en Centros No Participantes en Ensayos

October 01, 2015

News Daily News

RenalGuard 防止 TAVR 患者发生 AKI 的效果优于生理盐水

September 22, 2015

News Daily News

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

September 22, 2015

News Daily News

RenalGuard Evita la LRA en Pacientes TAVR Mejor que una Solución Salina Estándar

September 22, 2015

Advertisement

CoreValve Evolut R (Medtronic)

CoreValve Latin American Experience

Updates to CoreValve Extreme Risk Study Encouraging

Medtronic CoreValve® System Shows Positive Clinical Outcomes in New Patient Populations

CoreValve US Extreme Risk: Evaluation of a Self-Expanding Transcatheter Aortic Valve in Patients With Severe Aortic Stenosis at Extreme Risk for Surgery

CoreValve Extreme Risk Pivotal Trial: Improved Benefits Confirmed After 3 Years

Updates From the US CoreValve Studies 2: Reports From Selected Substudies

Updates From the US CoreValve Studies 1: Follow-up From the Extreme and High-Risk Subgroups

Symposia Highlights Variances Between Guideline-Based, ‘Real-World’ Indications for TAVR

Global TAVR Market Poised to Exceed DES Market by 2025

Asian TAVR Registry Shows Good Procedural and Clinical Results

Reduced Leaflet Motion in Bioprosthetic Aortic Valves Not Uncommon But Remedied by Anticoagulation

El Menor Movimiento de las Valvas en las Válvulas Aórticas Bioprotésicas es Habitual Pero puede Remediarse con el Uso de Anticoagulación

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

在采用TAVR的早期，在试验中心以外接受治疗的患者的死亡率并非更高

In the Early Days of TAVR, No Mortality Penalty for Patients Treated Outside of Trial Centers

En los Albores de la TAVR, No Hubo Más Mortalidad en Pacientes tratados en Centros No Participantes en Ensayos

RenalGuard 防止 TAVR 患者发生 AKI 的效果优于生理盐水

RenalGuard Protects TAVR Patients Against AKI Better Than Does Standard Saline

RenalGuard Evita la LRA en Pacientes TAVR Mejor que una Solución Salina Estándar

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content